Skip to content

Evaluation of Iodine Supplementation in Women With Pregnancy Associated With Gestational Diabetes

Evaluation of Iodine Supplementation in Women With Pregnancy Associated With Gestational Diabetes

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04683211
Acronym
IODIAB
Enrollment
100
Registered
2020-12-24
Start date
2021-01-05
Completion date
2021-05-11
Last updated
2026-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes

Keywords

Iodine intake, iodine supplementation, gestational diabetes

Brief summary

Iodine supplementation during pregnancy is recommended by the high health authority and by the World Health Organization during pregnancy. We would like to know if this supplementation is prescribed in a manner consistent with the recommendations in women diagnosed with gestational diabetes.

Detailed description

Physiological iodine requirements are increased in pregnant women, from 150 μg / day to 250 μg / day. The iodine intake is assessed by the iodine concentration in the urine, the target of which in pregnant women is ioduria between 150 and 250 μg / l. The general French population is not deficient in iodine according to the national nutrition health study in 2006-2007, with a median ioduria of 136 μg / l (therefore greater than 100 μg / l) for all elderly adults aged 18-74. However, according to French studies, the median ioduria of pregnant women is between 50 and 100 μg / l, which suggests a moderate iodine deficiency. To maintain euthyroidism, the mother must increase her T4 production by 40- 50% (10-150%), which requires an additional iodine intake of 150-250 μg / d The thyroid contains a reserve of iodine, but this is depleted during pregnancy in the absence of supplementation. Our study therefore aims to assess the amount of iodine supplementation prescribed in pregnant women diagnosed with gestational diabetes because this group of patients benefit from early specialized care for their pregnancies.

Interventions

OTHEREvaluation of iodine supplementation

survey of iodine supplementation

Sponsors

Centre Hospitalier Sud Francilien
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum

Inclusion criteria

* pregnant woman with gestational diabetes * age ≥ 18 years * subject informed of the study and not having opposed it.

Exclusion criteria

* already known pathology of the thyroid

Design outcomes

Primary

MeasureTime frameDescription
Iodine supplementationDay 0µg/day

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 23, 2026